Jazz Pharmaceuticals agreed to buy Actio Biosciences in a potentially $1.3 billion transaction, adding a clinical-stage KCNT1 epilepsy program to its pipeline. Under the deal terms, Actio receives $820 million upfront and could receive up to an additional $500 million tied to regulatory and sales milestones. Actio’s lead asset, ABS-1230, targets an ion channel implicated in KCNT1-related epilepsy and is being studied in children with meaningful seizure reductions in early proof-of-concept data. The company is also progressing additional development steps that could support future regulatory paths. Jazz expects to close the transaction in the final three months of the year and simultaneously spin out a separate early-stage entity funded by existing investors. Jazz will hold a minority stake in that spinout, aligning the move with its broader rare disease strategy. For the sector, the acquisition reflects continued appetite for venture-backed rare-disease assets with defined genetic targets and a clear unmet need profile.